Tofacitinib Key Intermediate by A.R. Life Sciences
Posted inHealth

Tofacitinib Key Intermediate by A.R. Life Sciences

Posted inHealth

Understanding Tofacitinib, Baricitinib, and Ruxolitinib:

Key Intermediates, Chemical Properties, and Pharmaceutical Benefits

Pharmaceutical advancements have significantly improved the treatment of autoimmune diseases, and Janus kinase (JAK) inhibitors have emerged as a breakthrough. Among them, Tofacitinib, Baricitinib, and Ruxolitinib play a crucial role in managing rheumatoid arthritis, psoriasis, and myelofibrosis. These medications are synthesized using high-quality pharmaceutical intermediates, ensuring purity and efficacy.

A.R. Life Sciences Pvt. Ltd has established itself as a leader in pharmaceutical interm ediate manufacturing, driving innovation and regulatory excellence. The company specializes in producing high-quality intermediates for active pharmaceutical ingredients (APIs) used in life-saving medications. Among the essential pharmaceutical compounds, Tofacitinib, Baricitinib, and Ruxolitinib are prominent JAK inhibitors that help treat autoimmune diseases like rheumatoid arthritis, psoriasis, and myelofibrosis. These treatments are made possible by the high-purity intermediates provided by leading API manufacturers, including A.R. Life Sciences Pvt. Ltd.

This article delves into the chemical properties, CAS numbers, and medical applications of Tofacitinib, Baricitinib, and Ruxolitinib, underscoring their role in pharmaceutical formulations.

1. Tofacitinib

  • IUPAC Name: 3-[(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]-3-oxopropanenitrile
  • CAS Number: 477600-75-2
  • Intermediate: 3-Bromo-6-Nitro-7H-Pyrrolo[2,3-d]pyrimidine
  • Intermediate CAS Number: 1001905-42-9
  • Chemical Properties:
    • Molecular Formula: C16H20N6O
    • Molecular Weight: 312.37 g/mol
    • Solubility: Soluble in DMSO and methanol
    • Appearance: White to off-white crystalline powder

Pharmaceutical Benefits: Tofacitinib is primarily used to treat rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ulcerative colitis (UC). It works by inhibiting JAK enzymes, reducing inflammation and immune response. High-quality intermediates ensure the purity and efficacy of the final product.

 

2. Baricitinib

  • IUPAC Name: 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl]acetonitrile
  • CAS Number: 1187594-09-7
  • Intermediate: 4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol
  • Intermediate CAS Number: 941685-27-4
  • Chemical Properties:
    • Molecular Formula: C16H17N7O2S
    • Molecular Weight: 371.42 g/mol
    • Solubility: Freely soluble in water and DMSO
    • Appearance: White to off-white solid

Pharmaceutical Benefits: Baricitinib is an oral JAK inhibitor used for treating moderate-to-severe rheumatoid arthritis and has been approved for COVID-19 treatment in some cases. It reduces inflammation and joint damage by selectively inhibiting JAK1 and JAK2 enzymes. The use of pure pharmaceutical intermediates is essential for its optimal therapeutic effect.

 

3. Ruxolitinib

  • IUPAC Name: (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(2-hydroxyethyl)-3-azabutan-1-one
  • CAS Number: 941678-49-5
  • Intermediate: 7H-Pyrrolo[2,3-d]pyrimidine-4-amine
  • Intermediate CAS Number: 22187-31-7
  • Chemical Properties:
    • Molecular Formula: C17H18N6O
    • Molecular Weight: 306.37 g/mol
    • Solubility: Soluble in DMSO, sparingly soluble in water
    • Appearance: White to beige solid

Pharmaceutical Benefits: Ruxolitinib is widely used to treat myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD). By inhibiting JAK1 and JAK2, it controls abnormal blood cell production and reduces spleen enlargement in patients with hematologic conditions. Ensuring high-purity intermediates guarantees its effectiveness and safety in clinical applications.

 

Importance of High-Quality Pharmaceutical Intermediates

The manufacturing of Tofacitinib, Baricitinib, and Ruxolitinib relies on precise chemical synthesis using well-characterized intermediates. A.R. Life Sciences Pvt. Ltd. is a trusted supplier of pharmaceutical intermediates and APIs, ensuring the top best standards of quality and regulatory compliance. The A.R.Life Science state-of-the-art production facilities and strict quality control make them a reliable partner for pharmaceutical manufacturers worldwide.

Conclusion

JAK inhibitors such as Tofacitinib, Baricitinib, and Ruxolitinib have transformed the treatment landscape for autoimmune diseases and blood disorders. The role of pharmaceutical intermediates is vital in producing these life-saving medications with superior purity and efficacy. A.R. Life Sciences Pvt. Ltd. remains committed to supplying top-quality intermediates to ensure the continued advancement of pharmaceutical innovations.

For high-quality pharmaceutical intermediates and APIs, A.R. Life Sciences Pvt. Ltd. stands as an industry leader, delivering excellence in every batch.